Others address issues that peptides do not
A Crowded Pipeline Means Strategic Differentiation Is Critical With over 100 assets in clinical development, ranging from multi-agonists like retatrutide (with potential for ~25% weight loss) to oral small molecules like orforglipron , the battle for clinical and commercial leadership will be intense [3]
If we do conduct additional testing in the future, results of testing would reflect administration of the Information-Transfer PRO-PM and OAS CAHPS because OAS CAHPS is now mandatory for ASCs
Current estimates in the litigation suggest that lower-value gastrointestinal cases may resolve in the tens of thousands of dollars, while severe injury cases involving surgery, permanent digestive impairment, or blindness could potentially result in substantially higher compensation
Red flags A claim says or implies FDA approval for anti-aging, recovery or performance without a product-specific label